Back to Journals » Journal of Experimental Pharmacology » Volume 13

Experimental Therapeutics in Treatment-Resistant Major Depressive Disorder

Authors Kaur M, Sanches M

Received 3 December 2020

Accepted for publication 27 January 2021

Published 24 February 2021 Volume 2021:13 Pages 181—196

DOI https://doi.org/10.2147/JEP.S259302

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Professor Bal Lokeshwar


Mandeep Kaur,1 Marsal Sanches2

1Department of Behavioral Medicine, Cone Health, Greensboro, NC, USA; 2UT Health Center of Excellence on Mood Disorders, Faillace Department of Psychiatry & Behavioral Sciences, McGovern Medical School, Houston, TX, USA

Correspondence: Mandeep Kaur
General, Child and Adolescent Psychiatrist Department of Behavioral Medicine, Cone Behavioral Health Hospital, 700 Walter Reed Drive, Greensboro, North Carolina, 27410, USA
Tel +1 (713) 540-2469
Email mandy.drmandeep@gmail.com

Abstract: Treatment-Resistant Depression (TRD) patients remain a challenging sub-division of patients with Major Depressive Disorder (MDD) in day to day clinical practice. As with any diagnostic condition, comprehensive evaluation, exclusion of other psychiatric conditions, assessment of co-morbid medical and psychiatric illnesses and psychosocial stressors are the keys to appropriate diagnosis and subsequent management. There are various management options available for the treatment of MDD, however, about 30% of the patients fail to achieve full remission of symptoms despite multiple trials and belong to this sub-category of MDD. This article brings forth discussion of other non-conventional medication and non-medication treatment alternatives that merit exploration of their efficacy in TRD. Many of the proposed novel medications and other treatment modalities such as Deep Brain Stimulation, exercise, yoga are already used for other medical and psychiatric disorders and have some evidence suggesting their potential benefits in TRD in conjunction with conventional medications or even as monotherapy. Nevertheless, more research is needed in this direction to establish effectiveness.

Keywords: major depressive disorder, treatment-resistant depression, anti-depressants, pharmacology, deep brain stimulation, HPA axis, psychedelic agents

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]